These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7578657

  • 21. Behavioral effects of naloxone infusion in obsessive-compulsive disorder.
    Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL.
    Biol Psychiatry; 1996 Jul 15; 40(2):154-6. PubMed ID: 8793049
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. 5-HT2A/C receptors do not mediate the attenuation of compulsive checking by mCPP in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD).
    Tucci MC, Dvorkin-Gheva A, Johnson E, Wong M, Szechtman H.
    Behav Brain Res; 2015 Feb 15; 279():211-7. PubMed ID: 25449840
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
    Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL.
    Arch Gen Psychiatry; 1988 Feb 15; 45(2):167-72. PubMed ID: 3276283
    [Abstract] [Full Text] [Related]

  • 31. Effects of the serotonergic agonist mCPP on male rats in the quinpirole sensitization model of obsessive-compulsive disorder (OCD).
    Tucci MC, Dvorkin-Gheva A, Graham D, Amodeo S, Cheon P, Kirk A, Peel J, Taji L, Szechtman H.
    Psychopharmacology (Berl); 2013 May 15; 227(2):277-85. PubMed ID: 23354534
    [Abstract] [Full Text] [Related]

  • 32. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder.
    Pian KL, Westenberg HG, van Megen HJ, den Boer JA.
    Psychopharmacology (Berl); 1998 Dec 15; 140(3):365-70. PubMed ID: 9877016
    [Abstract] [Full Text] [Related]

  • 33. The waking nightmare: an overview of obsessive compulsive disorder.
    Rapoport JL.
    J Clin Psychiatry; 1990 Nov 15; 51 Suppl():25-8. PubMed ID: 2228991
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
    Zohar J, Insel TR.
    Biol Psychiatry; 1987 Jun 15; 22(6):667-87. PubMed ID: 3036259
    [Abstract] [Full Text] [Related]

  • 38. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine.
    Simeon D, Hollander E, Stein DJ, DeCaria C, Cohen LJ, Saoud JB, Islam N, Hwang M.
    Psychiatry Res; 1995 Sep 29; 58(2):161-4. PubMed ID: 8570768
    [Abstract] [Full Text] [Related]

  • 39. Neurobiology of tryptophan depletion in depression: effects of m-chlorophenylpiperazine (mCPP).
    Price LH, Malison RT, McDougle CJ, McCance-Katz EF, Owen KR, Heninger GR.
    Neuropsychopharmacology; 1997 Nov 29; 17(5):342-50. PubMed ID: 9348549
    [Abstract] [Full Text] [Related]

  • 40. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
    Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR.
    Arch Gen Psychiatry; 1992 Jan 29; 49(1):21-8. PubMed ID: 1728249
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.